

**SUMMARY FROM SAC PROCEEDINGS (CEPI/SAC TC Nov 2017)**

The following Scientific Advisory Committee members participated:

<b>Committee members elect:</b>		<b>Non-voting members:</b>
<ul style="list-style-type: none"> <li>• Maharaj Kishan Bahn</li> <li>• Alan Barrett</li> <li>• Daniel Brasseur</li> <li>• Bernard Fanget</li> <li>• George Fu Gao</li> <li>• Jesse Goodman</li> <li>• Penny Heaton</li> <li>• David Kaslow</li> <li>• Michael Kurilla</li> <li>• Gunnstein Norheim</li> <li>• Stanley Plotkin</li> <li>• Connie Schmaljohn</li> <li>• Kenji Shibuya</li> <li>• Peter Smith</li> <li>• Gagandeep (Cherry) Kang</li> <li>• Yazdan Yazdanpanah (delegate)</li> </ul>	<p><b>Apologies</b></p> <ul style="list-style-type: none"> <li>• Mark Feinberg (Chair)</li> <li>• Gary Disbrow</li> <li>• Subhash Kapre</li> <li>• Yves Lévy</li> <li>• Kathleen Neuzil</li> <li>• Helen Rees</li> <li>• James Robinson</li> <li>• Amadou Sall</li> </ul>	<p><b>MNC representatives</b></p> <ul style="list-style-type: none"> <li>• Ali Allouche</li> <li>• Johan von Hoof</li> <li>• Kathrin Jansen</li> <li>• Jean Lang</li> </ul> <p><b>World Health Organization</b></p> <ul style="list-style-type: none"> <li>• Vasee Moorthy</li> </ul> <p><b>Invited experts</b></p> <ul style="list-style-type: none"> <li>• Sina Bavari (USAMRIID)</li> <li>• M. Louise Pitt (USAMRIID)</li> </ul>

**CEPI Secretariat participants:** Richard Hatchett (CEO), Eirik Bakka, Simone Blayer, Neil George Cherian, Carolyn Clark, Trygve Danielsen, Johan Holst, Karianne Johansen, Nicole Lurie, Hinta Meijerink, Gunnstein Norheim, Melanie Saville, Joseph Simmonds-Issler.

Richard Hatchett (CEPI CEO) chaired the meeting in Mark Feinberg's absence.

**Objectives** for the meeting:

1. To discuss any updates on CfP1 due diligence
2. To define Biological Standards, assays and animal models for priority diseases
3. To discuss any updates from CfP2
4. To discuss any updates on Ebola
5. To discuss a SAC Transition and Recalibration Phase
6. To discuss SAC Terms of Reference

### CfP1 update

Gunnstein Norheim, Director of Vaccine Sciences, gave an update on the due diligence process design, a step-wise process that takes place prior to signing any partnership agreements:



By Nov 8, three applicants had received a questionnaire from CEPI's technical due diligence team, and two of these applicants had responded in writing. The CEPI due diligence team will visit the first three candidates in the last three weeks of November, with one additional site visit taking place in December. The remaining applicant sites will be visited in the first two months of 2018.

### Biological Standards, Assays, and Animal Models for Lassa, MERS and Nipah

Johan Holst and Trygve Danielsen (CEPI Secretariat) provided an update from CEPI's working group on biological standards and assays. Sina Bavari and M. Louise Pitt provided a presentation of the Filovirus Animal Non-clinical Group (FANG) working group to support development of vaccines to contain outbreaks of EIDs. No SAC decisions were made.

### Preliminary Results from CfP2

Hinta Meijerink (CEPI Secretariat) provided an overview of preliminary results and the review process for CEPI's call for vaccine platform technologies. CEPI received 38 submissions for CfP2 Step 1, 33 of these submissions passed the eligibility check. The SAC was asked to provide input to templates for Step 2 of CfP2. It was decided that the new SAC would be asked to participate in the review process for Step 2 of CfP2.

### Update on Ebola

Carolyn Clark (CEPI Secretariat) provided an update on CEPI's strategy for "finishing the job on Ebola", including updates from the meeting on meeting on "Challenges in understanding vaccine-based protection against Ebola" in Washington DC, and the two task forces (one on animal models and the other on assays and standards). No decisions were made.

### Transition and Recalibration of SAC

Richard Hatchett provided information on the SAC transition and recalibration phase, and a summary of the major achievements of the preliminary SAC. The SAC was asked to provide input on lessons learned from the initial phase of CEPI. The SAC provided input on the Conflict of Interests Policy, reminding the CEPI Secretariat to also take intellectual conflicts of interests into account. No decisions were made.

### Revised SAC Terms of Reference (ToR)

Richard Hatchett provided information on the updated CEPI SAC Terms of Reference, noting the SAC would report to the CEO as opposed to the Board, although the SAC Chair would sit on the Board. The SAC reminded the CEPI Secretariat to align the Terms of Reference of the SAC and the Joint Coordination Group. The CEPI secretariat must have a clear, empowered responsibility and a robust project management and monitoring team. The SAC cannot successfully substitute for such, though individual members can provide support. A detailed dashboard on project progress could be brought to SAC periodically and as needed. The CEPI SAC should provide end-to-end vaccine development experience. The CEPI SAC advised considering having a defined quorum for SAC decision-making.